Ontology highlight
ABSTRACT:
SUBMITTER: McCormack FX
PROVIDER: S-EPMC3118601 | biostudies-literature | 2011 Apr
REPOSITORIES: biostudies-literature
McCormack Francis X FX Inoue Yoshikazu Y Moss Joel J Singer Lianne G LG Strange Charlie C Nakata Koh K Barker Alan F AF Chapman Jeffrey T JT Brantly Mark L ML Stocks James M JM Brown Kevin K KK Lynch Joseph P JP Goldberg Hilary J HJ Young Lisa R LR Kinder Brent W BW Downey Gregory P GP Sullivan Eugene J EJ Colby Thomas V TV McKay Roy T RT Cohen Marsha M MM Korbee Leslie L Taveira-DaSilva Angelo M AM Lee Hye-Seung HS Krischer Jeffrey P JP Trapnell Bruce C BC
The New England journal of medicine 20110316 17
<h4>Background</h4>Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is associated with inappropriate activation of mammalian target of rapamycin (mTOR) signaling, which regulates cellular growth and lymphangiogenesis. Sirolimus (also called rapamycin) inhibits mTOR and has shown promise in phase 1-2 trials involving patients with LAM.<h4>Methods</h4>We conducted a two-stage trial of sirolimus involving 89 patients with LAM who had moderate lung impairment--a 12-m ...[more]